Gene-guided blood thinner choice for heart disease patients
Part of Heart & circulation clinical trials.
This study tests whether using a genetic test to choose your blood thinner (clopidogrel or ticagrelor) can improve how well the medication works. You may qualify if you have stable heart disease or a recent heart attack and are scheduled for a stent procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have stable heart disease or a recent heart attack (acute coronary syndrome)
- You are scheduled to have a stent placed (percutaneous coronary intervention)
- You are willing to give a blood sample for genetic testing and platelet function testing
- You have not had a prior stroke (bleeding or clot-caused)
- You are not pregnant, on blood thinners, or have certain other serious medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether choosing a blood thinner based on your DNA can prevent more heart problems. If you've had a complex heart procedure, you may be able to get a medication that works best for your body.
This study compares two ways to manage blood thinners after a stent. It tests whether switching from stronger drugs (prasugrel or ticagrelor) to clopidogrel is safe and effective for long-term heart protection.
This trial compares two ways to choose blood thinners after a heart attack in people at high risk for bleeding. One way uses a genetic test to guide the choice, while the other uses a different approach.
This trial looks at whether using clopidogrel by itself (without aspirin) works for people after a new drug-eluting stent, based on a blood test of how your body processes the drug. It may help reduce “extra blood-thinning” if you have a certain genetic type that responds well to clopidogrel.
This trial compares using a genetic test to choose between two anti-clot medications (clopidogrel and ticagrelor) versus the usual approach of giving clopidogrel alone. It aims to see if personalized treatment can better prevent strokes in people with narrowed brain arteries.
This study tests whether switching early to a weaker anti-platelet medicine based on your genetics can reduce bleeding problems in people at high risk for bleeding after a heart attack. It compares this approach to the usual strategy of staying on a stronger anti-platelet medicine.
Hear when a new Coronary Arterial Disease (CAD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.